NextCure, Inc. (NXTC) intrinsic value & 10-year financials
NextCure, Inc. (NXTC) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $6.24
- Market cap
- $17.7M
- Revenue (FY2025)
- —
- Revenue growth (9-yr CAGR)
- 252.6%
- ROIC (10-yr avg)
- -57.5%
- Free cash flow (FY2025)
- —
NXTC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$55.8M | -$19.65 | — | — | -205.7% |
| FY2024 | — | -$55.7M | -$1.99 | -$41.3M | — | -74.1% |
| FY2023 | — | -$62.7M | -$2.25 | -$53.8M | — | -49.2% |
| FY2022 | — | -$74.7M | -$2.69 | -$56.0M | — | -40.6% |
| FY2021 | — | -$69.4M | -$2.51 | -$59.6M | — | -28.6% |
| FY2020 | $22.4M | -$36.6M | -$1.33 | -$52.1M | -184.2% | -13.1% |
| FY2019 | $6.3M | -$33.7M | — | -$39.0M | -590.5% | -60.9% |
| FY2018 | — | -$22.8M | — | $4.9M | — | 12.6% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NextCure, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NextCure, Inc. has historically struggled to out-earn its cost of capital, averaging just -32.0% ROIC.
NextCure, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NextCure, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-652.69 per share.